$4.15
-0.32 (-7.16%)
Open$4.30
Previous Close$4.47
Day High$4.35
Day Low$4.13
52W High$5.54
52W Low$0.75
Volume—
Avg Volume534.2K
Market Cap281.62M
P/E Ratio—
EPS$-0.47
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+127.0% upside
Current
$4.15
$4.15
Target
$9.42
$9.42
$6.99
$9.42 avg
$10.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 10.71M | 132.26M | 127.36M |
| Net Income | -87,736,514 | 2.80M | 2.65M |
| Profit Margin | -819.6% | 2.1% | 2.1% |
| EBITDA | -86,230,017 | 4.42M | 4.16M |
| Free Cash Flow | — | 2.17M | 2.21M |
| Rev Growth | — | +3.8% | -1.6% |
| Debt/Equity | — | 0.63 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |